Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several safety/reproductive claims are inconsistent with the label excerpts provided (notably: contraindication during pregnancy and lactation contraindication). Reproductive toxicity is supported, but some specific details (e.g., contraception timing and embryo-fetal toxicity language) conflict with the label wording/timing. Additional items (genotoxic effects, pregnancy category, registry) are unsupported by the supplied excerpts.
Category Scores
Accurate Statements
Lurbinectedin can cause embryo-fetal developmental toxicity and death when administered to pregnant women.
Supported in concept: 5.5 Embryo-Fetal Toxicity: “ZEPZELCA can cause fetal harm when administered to a pregnant woman.” (The supplied excerpt also states embryo-lethality and is based on animal data/mechanism.)
Lurbinectedin can cause fetal harm when administered to pregnant women.
5.5 Embryo-Fetal Toxicity: “ZEPZELCA can cause fetal harm when administered to a pregnant woman.”
Animal reproduction studies indicate lurbinectedin produces embryolethality and malformations at doses lower than human equivalents.
Partially supported: 8.3 states “ZEPZELCA can cause embryolethality…” and 5.5 refers to animal data and mechanism; however, the excerpt does not provide malformations or “0.04–0.3 times” dosing specifics.
There are no adequate human data regarding lurbinectedin use in pregnancy.
Not supported or contradicted by the provided excerpts (no “adequate human data” statement included).
Women of reproductive potential require contraception during lurbinectedin treatment and for 6 months after the last dose.
Partially supported: 8.3 requires effective contraception for females after the last dose, but the provided excerpt specifies 7 months—not 6.
Males require contraception for 4 months after lurbinectedin treatment.
8.3 Females and Males of Reproductive Potential: “Advise males… use effective contraception… for 4 months after the last dose.”
Unsupported Statements
Lurbinectedin (Zepzelca) is contraindicated during pregnancy.
Label excerpt provided states Contraindications: “None.” No pregnancy contraindication language is included.
Animal reproduction studies indicate lurbinectedin produces embryolethality and malformations at doses lower than human equivalents.
The provided excerpts confirm embryo-lethality and fetal harm but do not mention malformations or dose equivalence thresholds.
In rats and rabbits, lurbinectedin caused embryo-fetal death.
The provided excerpts do not specify species (rats/rabbits) or describe embryo-fetal death outcomes.
In rats and rabbits, lurbinectedin reduced fetal weight.
Not described in the supplied excerpts.
In rats and rabbits, lurbinectedin caused skeletal or organ abnormalities.
Not described in the supplied excerpts.
In rats and rabbits, these effects occurred at exposures 0.04–0.3 times the human clinical dose.
Not described in the supplied excerpts.
There are no adequate human data regarding lurbinectedin use in pregnancy.
No such statement appears in the provided excerpts.
Lurbinectedin has genotoxic effects.
No genotoxicity statement appears in the provided excerpts (only embryo-fetal toxicity, myelosuppression, hepatotoxicity, etc.).
Women of reproductive potential require contraception during lurbinectedin treatment and for 6 months after the last dose.
Timing is not supported as stated; the excerpt specifies 7 months after the last dose.
A pregnancy exposure registry exists for lurbinectedin.
No pregnancy exposure registry statement appears in the provided excerpts.
Lactation is contraindicated with lurbinectedin due to potential secretion.
The excerpt states: “Advise women not to breastfeed during treatment… and for 2 weeks after the last dose.” It does not state contraindication or “potential secretion.”
The FDA pregnancy category for lurbinectedin is not assigned.
The provided excerpts do not mention pregnancy category assignment.
Contradictions
High
AI Statement
Lurbinectedin (Zepzelca) is contraindicated during pregnancy.
Label Reference
Contraindications (Section 4): “None.”
Moderate
AI Statement
Women of reproductive potential require contraception during lurbinectedin treatment and for 6 months after the last dose.
Label Reference
8.3 Females and Males of Reproductive Potential: “use effective contraception… for 7 months after the last dose.”
Moderate
AI Statement
Lactation is contraindicated with lurbinectedin due to potential secretion.
Label Reference
8.2 Lactation: “Advise women not to breastfeed during treatment… and for 2 weeks after the last dose.” (No contraindication statement and no “potential secretion” language in excerpt.)
Important Omissions
Label excerpt specifies contraception timing as 7 months (females) and 4 months (males) after the last dose; the claims included a 6-month figure for females. If the AI response intended to reflect label timing, it omitted the correct 7-month duration.
Importance:
Moderate
If lactation guidance was intended, the label excerpt provides a breastfeeding avoidance period (2 weeks after last dose) rather than contraindication. The AI response omitted the specific duration from the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Contradicted label statements regarding pregnancy contraindication and incorrect contraception timing for females could lead to unsafe or inaccurate counseling. Lactation guidance was also mischaracterized as contraindicated rather than advising against breastfeeding for 2 weeks after the last dose.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Key label conflicts and incorrect specifics for pregnancy/lactation and contraception timing (pregnancy contraindication claim; female contraception duration 6 vs 7 months; lactation described as contraindicated rather than advising not to breastfeed for 2 weeks).
Suggested Improvement
Remove/replace contradicted contraindication statements (Section 4: “None.”). Align contraception duration to label (females: 7 months after last dose; males: 4 months). Replace lactation contraindication language with the label’s breastfeeding avoidance statement (no breastfeeding during treatment and for 2 weeks after last dose). Limit claims about animal species/exposures and genotoxicity to what is present in the provided label excerpts.